171 related articles for article (PubMed ID: 7101243)
1. Biochemical and metabolic aspects of platelet dysfunction in chronic myeloproliferative disorders.
Pareti FI; Gugliotta L; Mannucci L; Guarini A; Mannucci PM
Thromb Haemost; 1982 Apr; 47(2):84-9. PubMed ID: 7101243
[TBL] [Abstract][Full Text] [Related]
2. Abnormalities of epinephrine-induced platelet aggregation and adenine nucleotides in myeloproliferative disorders.
Yamamoto K; Sekiguchi E; Takatani O
Thromb Haemost; 1984 Dec; 52(3):292-6. PubMed ID: 6531753
[TBL] [Abstract][Full Text] [Related]
3. Correlation between prolonged bleeding time and depletion of platelet dense granule ADP in patients with myelodysplastic and myeloproliferative disorders.
Malpass TW; Savage B; Hanson SR; Slichter SJ; Harker LA
J Lab Clin Med; 1984 Jun; 103(6):894-904. PubMed ID: 6233383
[TBL] [Abstract][Full Text] [Related]
4. Abnormalities of platelet adenine nucleotides in patients with myeloproliferative disorders.
Nishimura J; Okamoto S; Ibayashi H
Thromb Haemost; 1979 Jun; 41(4):787-95. PubMed ID: 483250
[TBL] [Abstract][Full Text] [Related]
5. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
6. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
7. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
8. Platelets in myeloproliferative disorders. II. Serotonin uptake and storage: correlations with mepacrine labelled dense bodies and with platelet density.
Caranobe C; Sie P; Nouvel C; Laurent G; Pris J; Boneu B
Scand J Haematol; 1980 Oct; 25(4):289-95. PubMed ID: 7209398
[TBL] [Abstract][Full Text] [Related]
9. Platelet abnormalities in myeloproliferative disorders.
Holme S; Murphy S
Clin Lab Med; 1990 Dec; 10(4):873-88. PubMed ID: 2272179
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous study of platelets and phagocytes in myeloproliferative disorders.
Laharrague PF; Corberand JX; Fillola G; Boneu BP; Pris JF
Biomed Pharmacother; 1984; 38(9-10):462-5. PubMed ID: 6597727
[TBL] [Abstract][Full Text] [Related]
11. Gray platelet syndrome: alpha-granule deficiency. Its influence on platelet function.
Levy-Toledano S; Caen JP; Breton-Gorius J; Rendu F; Cywiner-Golenzer C; Dupuy E; Legrand Y; Maclouf J
J Lab Clin Med; 1981 Dec; 98(6):831-48. PubMed ID: 6458643
[TBL] [Abstract][Full Text] [Related]
12. Increased response to arachidonic acid and U-46619 and resistance to inhibitory prostaglandins in patients with chronic myeloproliferative disorders.
Cortelazzo S; Galli M; Castagna D; Viero P; de Gaetano G; Barbui T
Thromb Haemost; 1988 Feb; 59(1):73-6. PubMed ID: 3129810
[TBL] [Abstract][Full Text] [Related]
13. [Blood platelet changes in myeloproliferative disorders].
D'Angelo G; Calvano D; Giardini C
Minerva Med; 1988 Oct; 79(10):853-7. PubMed ID: 3141845
[TBL] [Abstract][Full Text] [Related]
14. [ATP and ADP of platelets in chronic myeloproliferative disorders and multiple myeloma].
Terada H; Ohshima M
Rinsho Ketsueki; 1989 Jan; 30(1):22-8. PubMed ID: 2716195
[TBL] [Abstract][Full Text] [Related]
15. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
16. Combined defect in membrane expression and activation of platelet GPIIb--IIIa complex without primary sequence abnormalities in myeloproliferative disease.
Kaplan R; Gabbeta J; Sun L; Mao GF; Rao AK
Br J Haematol; 2000 Dec; 111(3):954-64. PubMed ID: 11122160
[TBL] [Abstract][Full Text] [Related]
17. [Defects in the prostaglandin system. VIII. A pathologic thrombocyte population in myeloproliferative syndrome, which forms no thromboxane from exogenous arachidonic acid].
Sinzinger H; Gisslinger H; Linkesch W; Ludwig H; Flener R; Peskar BA
Wien Klin Wochenschr; 1988 Nov; 100(21):715-8. PubMed ID: 3149432
[TBL] [Abstract][Full Text] [Related]
18. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules.
Gerrard JM; Phillips DR; Rao GH; Plow EF; Walz DA; Ross R; Harker LA; White JG
J Clin Invest; 1980 Jul; 66(1):102-9. PubMed ID: 6156948
[TBL] [Abstract][Full Text] [Related]
19. Membrane defects in inherited disorders of platelet function.
White JG
Am J Pediatr Hematol Oncol; 1982; 4(1):83-94. PubMed ID: 7091581
[TBL] [Abstract][Full Text] [Related]
20. Adenine nucleotides, serotonin, and aggregation properties of platelets of blue foxes (Alopex lagopus) with the Chediak-Higashi syndrome.
Sjaastad OV; Blom AK; Stormorken H; Nes N
Am J Med Genet; 1990 Mar; 35(3):373-8. PubMed ID: 2309785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
